First Tracks Biotherapeutics, Inc. (TRAX), a clinical-stage biotechnology company, reported third-quarter results for the period ended September 30, 2026, and provided a business update.
First Tracks Biotherapeutics develops antibody therapies for autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator.
Third Quarter 2026 Results
After the AnaptysBio-First Tracks Biotherapeutics separation on April 20, 2026, reported results for the pre-separation periods include the assets, liabilities, and expenses of both companies.
For the third quarter of 2026, net loss narrowed to $31.4 million, or $0.88 per share, compared to a net loss of $41.9 million, or $1.50 per share.
Near Term Milestones
For ANB033, Phase 1b Cohort 2 in celiac disease (CeD) aims to assess mucosal healing through 12 weeks. Enrollment is expected to be completed, with top-line data anticipated in the first quarter of 2027.
The company anticipates initiating a late-stage clinical trial for ANB033 in CeD in 2027.
In ad...